Latest News

The European Commission has approved encorafenib plus cetuximab and FOLFOX as the first BRAF-targeted regimen authorized in the EU for first-line BRAF V600E–mutant metastatic colorectal cancer.

Experts discussed the integration of GLP-1 agonists and lifestyle interventions to mitigate obesity-related cancer risks and improve long-term survival.

Chinmay Jani, MD, discussed work he presented at the 2026 ASCO Meeting and future directions for precision medicine and clinical trials in lung cancer care.

Qualitative interviews with 43 patients on capivasertib plus fulvestrant found the 4-on/3-off dosing schedule broadly acceptable, while identifying gaps in hyperglycemia recognition and willingness to use supportive medications.

This 13-case pictorial review from the University of Rochester Medical Center illustrates the variable mammography, ultrasound, and MRI presentations of pleomorphic invasive lobular carcinoma to support timely interdisciplinary diagnosis.

A panel of exerts discussed key takeaways happening in the field of HER2+ metastatic breast cancer.

Those with TP53-mutated disease may benefit from continuous BTK inhibitor therapy, although limited-duration therapy is worthy of discussion.

This pictorial case series of 5 intramammary spindle-cell lesions demonstrates characteristics that support confident benign diagnosis after biopsy without surgical excision.

This prospective study found that diffuse optical spectroscopy identified elevated collagen as a significant biomarker for breast cancer malignancy, supporting further investigation of DOS as a noninvasive complement to biopsy.

Using spatial proteomics and nanomechanical profiling across two clinical cohorts, investigators identified hypoxia-driven epithelial-to-mesenchymal transition as a biological signature linking aggressive biomechanical phenotypes to poor breast cancer outcomes.

A theory-driven paper planner combined with a digital AI companion demonstrated high acceptability and improved treatment confidence among patients with metastatic TNBC initiating ADC therapy.

TRIDENT failed to show an OS benefit for TTFields started during chemoradiation vs the maintenance-phase approach in newly diagnosed glioblastoma.

Findings from the phase 3 SUNMO trial support the regulatory decision regarding the mosunetuzumab-based regimen for this relapsed/refractory population.

In an expert-led review of pivotal clinical trial data presented at the 2026 ASCO Annual Meeting, CancerNetwork® spoke with oncology experts in the renal cell carcinoma (RCC), Merkel cell carcinoma, and chronic myeloid leukemia (CML) spaces to break down key abstracts at the conference.

A panel of exerts discussed key takeaways happening in the field of cutaneous squamous cell carcinoma.

In this Florida Cancer Data System mediation analysis, racialized economic segregation and insurance disadvantage explained 29% of the racial disparity in advanced breast cancer stage at diagnosis between Black and White women.

In this Florida Cancer Data System analysis, structural racism and health insurance disadvantage together mediated nearly 8% of the racial disparity in TNBC between Black and White women.

New ASCO 2026 data reinforced the importance of multidisciplinary coordination and patient-centered decision-making when considering cystectomy omission.

The 2025 ICE-T Symposium highlighted expansion beyond BCMA to additional targets such as GPRC5D and FcRH5.

The investigators concluded that the impact of autologous stem cell transplantation with ibrutinib cannot be determined vs ibrutinib alone.

Updated NCCN guidelines for CNS cancers now recommend CSF-based tumor-derived DNA testing for patients with biopsy-infeasible high-grade glioma or glioblastoma.

Julie M. Vose, MD, MBA, discussed how the digital age is impacting oncology care.

This retrospective claims analysis found neutropenia carried substantial economic burden in HR+/HER2– and triple-negative mBC, with the highest neutropenia-related costs seen during sacituzumab govitecan regimens.

This review of monarchE and TRADE data demonstrates that abemaciclib dose modifications manage treatment-related adverse events without compromising efficacy in high-risk HR+, HER2− early breast cancer.

A phase 3 trial with givastomig plus nivolumab and chemotherapy in first-line HER2-negative metastatic gastric cancer is planned in Q4 2026.

This year’s EHA Congress saw potential advances across multiple myeloma, leukemia, lymphoma, and other hematologic malignancy populations.

Treatment with ADCs for metastatic TNBC comes with a unique set of toxicities, and know how to manage, or adjust treatment as needed is important.

This descriptive systematic review of 14 studies found diagnostic delay in PABC was common and multifactorial, driven by both patient- and provider-related factors including symptom misattribution to pregnancy.

This phase 1/2 trial assessed HER2 BATs combined with pembrolizumab in metastatic breast cancer, finding the regimen safe and well tolerated with stable disease as the best response in 17 evaluable patients.

Panelists discussed 4 trials, which focused on 3 different ADCs and how each one is being utilized in their clinical practice.

Among 3-to-25-year-old patients with slow, early responses to chemotherapy with newly diagnosed classic Hodgkin lymphoma, pembrolizumab showed an ORR of 98%.